255 related articles for article (PubMed ID: 11965606)
21. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide.
Capello A; Krenning EP; Breeman WA; Bernard BF; de Jong M
J Nucl Med; 2003 Jan; 44(1):98-104. PubMed ID: 12515882
[TBL] [Abstract][Full Text] [Related]
22. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
Gupta SK; Singla S; Bal C
Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
[TBL] [Abstract][Full Text] [Related]
23. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
24. Treatment with high dose [(111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors--evaluation of therapeutic and toxic effects.
Tiensuu Janson E; Eriksson B; Oberg K; Skogseid B; Ohrvall U; Nilsson S; Westlin JE
Acta Oncol; 1999; 38(3):373-7. PubMed ID: 10380830
[TBL] [Abstract][Full Text] [Related]
25. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.
Virgolini I; Britton K; Buscombe J; Moncayo R; Paganelli G; Riva P
Semin Nucl Med; 2002 Apr; 32(2):148-55. PubMed ID: 11965610
[TBL] [Abstract][Full Text] [Related]
26. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
28. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
[TBL] [Abstract][Full Text] [Related]
29. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
[TBL] [Abstract][Full Text] [Related]
31. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study.
Stokkel MP; Verkooijen RB; Bouwsma H; Smit JW
Nucl Med Commun; 2004 Jul; 25(7):683-90. PubMed ID: 15208495
[TBL] [Abstract][Full Text] [Related]
32. Radiolabeled peptides in the diagnosis and therapy of oncological diseases.
Weiner RE; Thakur ML
Appl Radiat Isot; 2002 Nov; 57(5):749-63. PubMed ID: 12433051
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.
Menda Y; O'Dorisio MS; Kao S; Khanna G; Michael S; Connolly M; Babich J; O'Dorisio T; Bushnell D; Madsen M
J Nucl Med; 2010 Oct; 51(10):1524-31. PubMed ID: 20847174
[TBL] [Abstract][Full Text] [Related]
34. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group.
Chinol M; Bodei L; Cremonesi M; Paganelli G
Semin Nucl Med; 2002 Apr; 32(2):141-7. PubMed ID: 11965609
[TBL] [Abstract][Full Text] [Related]
35. Yttrium-90 DOTATOC: first clinical results.
Otte A; Herrmann R; Heppeler A; Behe M; Jermann E; Powell P; Maecke HR; Muller J
Eur J Nucl Med; 1999 Nov; 26(11):1439-47. PubMed ID: 10552085
[TBL] [Abstract][Full Text] [Related]
36. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver.
Slooter GD; Breeman WA; Marquet RL; Krenning EP; van Eijck CH
Int J Cancer; 1999 May; 81(5):767-71. PubMed ID: 10328231
[TBL] [Abstract][Full Text] [Related]
37. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
[TBL] [Abstract][Full Text] [Related]
38. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
Otte A; Jermann E; Behe M; Goetze M; Bucher HC; Roser HW; Heppeler A; Mueller-Brand J; Maecke HR
Eur J Nucl Med; 1997 Jul; 24(7):792-5. PubMed ID: 9211767
[TBL] [Abstract][Full Text] [Related]
39. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
40. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]